RISKS. Atorvastatin has a well-established safety and adverse reactions profiles and is already used in the hemodialysis population for different indications. Chronic Kidney Disease participants enrolled in this trial have elevated risks of cardiovascular events, and although only statin-naïve patients or statin-free in the last 6 months prior to enrollment will be eligible to participate, it is likely that many of these patients already have an indication for statin treatment. In order to minimize the occurrence of potential adverse effects, the investigators will carefully evaluate the potential candidates for the study prior to the enrollment and will follow the 2013 ACC/AHA blood cholesterol guidelines recommendations. The investigators will do fasting lipid panel, hepatic transaminase levels, CRP and CPK at baseline, at 5-6 weeks after therapy initiation, and at the final follow up at 8 weeks of therapy. There are no additional risks associated with the procedures that are going to be performed in this study other than phlebotomy and surgery-related complications.